Inotuzumab ozogamicin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Inotuzumab ozogamicin
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD22
Clinical data
Trade names Besponsa
ATC code
Synonyms CMC-544
CAS Number
  • none
Chemical and physical data
Formula C6518H10002N1738O2036S42
Molar mass 150,000 g/mol
 NYesY (what is this?)  (verify)

Inotuzumab ozogamicin (trade name Besponsa) is an antibody-drug conjugate for the treatment of cancers.[1] It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).[2]

This drug is being developed by Pfizer and UCB.

It has undergone numerous clinical trials, including two phase II trials for non-Hodgkin lymphoma (NHL). [3]

A Phase III trial in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not candidates for intensive high-dose chemotherapy was terminated for futility.[4]

As of April 2016 ten clinical trials were active (including one phase III for acute lymphoblastic leukemia (ALL)[5]), six still recruiting.[3]

See also[edit]


  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Inotuzumab ozogamicin, American Medical Association.
  2. ^ Takeshita, A; Shinjo, K; Yamakage, N; Ono, T; Hirano, I; Matsui, H; Shigeno, K; Nakamura, S; Tobita, T; Maekawa, M (2009). "CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.". British journal of haematology. 146 (1): 34–43. PMID 19388933. doi:10.1111/j.1365-2141.2009.07701.x. 
  3. ^ a b
  4. ^ Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility. May 2013
  5. ^ An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)